Stable, genetically engineered F(ab′)2 fragments of chimeric TNT-3 expressed in mammalian cells

Hybridoma and Hybridomics

Volumn 21, Issue 1, 2002, Pages 11-18

  Khawli, Leslie A ^a   Biela, Barbara H ^a   Hu, Peisheng ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYSTEINE; DODECYL SULFATE SODIUM; GLUTAMATE AMMONIA LIGASE; HISTIDINE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PROTEIN TNT 3; REAGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BODY DISTRIBUTION; CONTROLLED STUDY; GENETIC ENGINEERING; IN VIVO STUDY; MAMMAL CELL; MOUSE; MYELOMA; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PURIFICATION; TUMOR NECROSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGENS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GENETIC VECTORS; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; MICE, INBRED BALB C; NEOPLASMS; PLASMIDS; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA; MAMMALIA; MURINAE;

EID: 0036076764     PISSN: 15368599     EISSN: None     Source Type: Journal    
DOI: 10.1089/15368590252917593     Document Type: Article

References (50)

1. Genetically engineered antibodies: Progress and prospects
2. The current role of immunohistochemistry in diagnostic pathology
3. Twenty years with monoclonal antibodies: State of the art - Where do we go?
4. Monoclonal antibody-based therapy
5. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies
6. Optimism after much pessimism: What next?
7. 2
8. 2 and Fab′ in mice
9. Monoclonal antibodies in cancer detection and therapy
10. 2 fragments for radioimmuno-imaging of human colon cancer in nude mice
11. Pharmacokinetics and biodistribution of genetically-engineered antibodies
12. 2 fragments from mouse IgG of various subclases
13. Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinoma
14. 2 suitable for clinical use from mouse IgG1
15. 2 fragments in high yield from murine IgG1 monoclonal antibodies
16. The development of monoclonal antibodies for the therapy of cancer
17. Recombinant antibody fragments
18. Antibody engineering: Comparison of bacterial, yeast, insect and mammalian expression systems
19. High-level Escherichia coli expression and production of a bivalent humanized antibody fragment
20. 2 formation in Escherichia coli and for improved in vivo stability
21. 2 molecules made from Escherichia coli produced Fab′ with hinge sequences conferring increased serum survival in an animal model
22. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker
23. A novel method for the detection of necrotic lesions in human cancers
24. Tumor necrosis imaging and treatment of solid tumors
25. A new chemically modified chimeric monoclonal antibody directed against DNA for the immunotherapy of solid tumors
26. Cytology of Burkitt's tumour (African lymphoma)
27. Characterization and responsiveness of the Madison 109 lung carcinoma to various antitumor agents
28. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells
29. The random peptide library-assisted engineering of a C-terminal affinity peptide, useful for the detection and purification of a functional Ig Fv fragment
30. Chimeric CLL-1 antibody fusion proteins containing Granulocyte Macrophage Colony-Stimulating Factor or Interleukin-1 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties
31. Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors
32. The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay: An analysis of the interaction between hybridoma proteins and influenza virus
33. The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G
34. Comparison of complete versus fragmented technetium-99m-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer
35. H2 domain and directed against the disialoganglioside GD2
36. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins
37. Engineering novel antibody molecules
38. Generating improved single-chain Fv molecules for tumor targeting
39. Monoclonal antibody production: Problems and solutions
40. Recent advances in the large-scale production of antibody using lower eukaryotic microorganisms
41. Considerations for in vitro monoclonal antibody production
42. Affinity fusion strategies for detection, purification and immobilization of recombinant antibodies
43. Antibody binding sites
44. The hierarchy of mutations influencing the folding of antibody domains in Escherichia coli
45. Differences in sequence-specific expression of two anti-arsonic Fabs in E. coli
46. 2
47. Inverted Fab2s (IFab2s): Engineering and expression of novel, dimeric molecules with the molecular weight of 100, 000
48. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxocity and anti-tumor efficacy
49. Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy
50. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab′ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: Results of a pivotal, phase III trial